Community Health Systems Stock Earnings Reports

Community Health Systems (CHS) reported first quarter 2026 results that were toward the low end of expectations. Adjusted EBITDA was $309 million, down 17.8% year-over-year, with a margin of 10.4%. Same-store net revenue rose 3.1% driven primarily by a 3.7% increase in net revenue per adjusted admission, but same-store adjusted admissions declined 0.5% and same-store inpatient admissions declined 1.3%. Management attributed volume and payer-mix weakness to macroeconomic pressure (high-deductible commercial/exchange patients delaying care), more aggressive managed-care preauthorization/denial activity, and recent divestitures that produced an approximate $50 million year-over-year EBITDA drag in the quarter. The Georgia state directed payment program contributed about $25 million in the quarter (largely retroactive to prior periods), partially offset by out-of-period Indiana provider tax increases.

Cash flows from operations were a use of $297 million (versus positive $120 million prior year), largely due to timing items (Medicaid supplemental/payment and provider tax timing (~$90M), a $50M–$60M Medicare Advantage AR buildup, annual bonus payments (~$50M), AP timing, and a deferred interest payment on 2034 notes). CHS completed several divestitures in the quarter generating over $1.1 billion gross proceeds, used $223 million to redeem 2032 notes, and announced a pending sale of four Arkansas hospitals for $112 million (expected to close in Q2). Net debt is expected to fall to about $9.3 billion after the Arkansas sale (from $10.1B at year-end 2025). Leverage improved modestly to ~6.5x at quarter end.

CHS is investing in ambulatory surgery centers (ASCs) — including a pending majority stake in the Surgical Institute of Alabama and other ASC activity (~$85 million total) — and opened/expanded ASCs to extend outpatient surgical capacity within existing markets. Management emphasized operational priorities: quality, patient experience, physician experience and employee satisfaction, noting expected improvements in Leapfrog safety grades (expecting up to ~80% of hospitals at A/B) and CMS star ratings (expecting 56% at 3+ stars) when new ratings publish.

Guidance for full-year 2026 remains unchanged: adjusted EBITDA range of $1.34 billion to $1.49 billion. Management expects low-single-digit volume growth for the year (anticipating recovery in the back half), and noted potential upside or downside from evolving state-directed payment programs, the Rural Health Transformation Fund, ACA premium subsidy dynamics, and Medicaid redeterminations/work requirements. Key near-term risks are continued demand softness among high-deductible exchange/commercial patients, managed-care payment behaviors, and timing of supplemental/state program payments.